Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

(Reuters) - Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that seeks to help body's immune system fight cancer as the drugmaker chases its rivals in a lucrative market.